Aurisco PharmaceuticalLtd 관리

관리 기준 확인 2/4

Aurisco PharmaceuticalLtd CEO는 Dingjun Chu, Jun2017 에 임명되었습니다 의 임기는 7.42 년입니다. 는 CN¥ 69.92M 가치에 해당하는 회사 주식의 0.81% 직접 소유합니다. 69.92M. 경영진과 이사회의 평균 재임 기간은 각각 7.4 년과 7.4 년입니다.

주요 정보

Dingjun Chu

최고 경영자

CN¥1.7m

총 보상

CEO 급여 비율	n/a
CEO 임기	7.4yrs
CEO 소유권	0.8%
경영진 평균 재임 기간	7.4yrs
이사회 평균 재임 기간	7.4yrs

최근 관리 업데이트

Recent updates

Is Aurisco PharmaceuticalLtd (SHSE:605116) A Risky Investment?

Sep 19

Is Now The Time To Put Aurisco PharmaceuticalLtd (SHSE:605116) On Your Watchlist?

Aug 14

Investors Interested In Aurisco Pharmaceutical Co.,Ltd.'s (SHSE:605116) Earnings

Jun 28

Aurisco PharmaceuticalLtd (SHSE:605116) Has A Pretty Healthy Balance Sheet

Jun 07

Investors Shouldn't Be Too Comfortable With Aurisco PharmaceuticalLtd's (SHSE:605116) Earnings

May 12

Here's Why We Think Aurisco PharmaceuticalLtd (SHSE:605116) Might Deserve Your Attention Today

Apr 22

CEO

Dingjun Chu (51 yo)

7.4yrs

테뉴어

CN¥1,713,284

보상

Mr. Dingjun Chu is General Manager and Director of Aurisco Pharmaceutical Co.,Ltd. since June 01, 2017.

리더십 팀

이름	위치	테뉴어	보상	소유권
Dingjun Chu	GM & Director	7.4yrs	CN¥1.71m	0.81% CN¥ 69.9m
Liqin Zhang	Deputy GM & Director of Sales	7.4yrs	CN¥1.29m	0.044% CN¥ 3.8m
Guoping Wang	Deputy GM & Director	7.4yrs	CN¥1.75m	데이터 없음
Fangfang Li	Board Secretary	7.4yrs	CN¥1.13m	데이터 없음
Zhenping Zhao	Deputy General Manager	6.7yrs	CN¥906.76k	0.062% CN¥ 5.3m

7.4yrs

평균 재임 기간

51yo

평균 연령

경험이 풍부한 관리: 605116 의 관리팀은 노련하고 경험 (평균 재직 기간 7.4 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Dingjun Chu	GM & Director	7.4yrs	CN¥1.71m	0.81% CN¥ 69.9m
Guoping Wang	Deputy GM & Director	4.5yrs	CN¥1.75m	데이터 없음
Yizhou Chu	Vice Chairman	7.4yrs	CN¥76.12k	31.71% CN¥ 2.7b
Zhien Peng	Chairman of the Board	7.4yrs	CN¥1.36m	37.81% CN¥ 3.3b
Peijing Qiu	Director	7.4yrs	CN¥1.08m	2.75% CN¥ 236.8m
Ping Jin	Chairman of the Supervisory Board	7.4yrs	데이터 없음	0.81% CN¥ 69.9m
Yue Zhou	Supervisor	7.4yrs	데이터 없음	데이터 없음

7.4yrs

평균 재임 기간

58yo

평균 연령

경험이 풍부한 이사회: 605116 의 이사회는 경험(평균 재직 기간 7.4 년)으로 간주됩니다.

Aurisco PharmaceuticalLtd 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Aurisco Pharmaceutical Co.,Ltd., Annual General Meeting, May 20, 2024

No independent directors

No independent directors

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.24 (vs CN¥0.32 in 3Q 2023)

Aurisco Pharmaceutical Co.,Ltd. to Report Q3, 2024 Results on Oct 25, 2024

Investor sentiment improves as stock rises 20%

Is Aurisco PharmaceuticalLtd (SHSE:605116) A Risky Investment?

Is Now The Time To Put Aurisco PharmaceuticalLtd (SHSE:605116) On Your Watchlist?

Aurisco Pharmaceutical Co.,Ltd. to Report First Half, 2024 Results on Aug 29, 2024

Investors Interested In Aurisco Pharmaceutical Co.,Ltd.'s (SHSE:605116) Earnings

Aurisco PharmaceuticalLtd (SHSE:605116) Has A Pretty Healthy Balance Sheet

Investors Shouldn't Be Too Comfortable With Aurisco PharmaceuticalLtd's (SHSE:605116) Earnings

Aurisco Pharmaceutical Co.,Ltd., Annual General Meeting, May 20, 2024

Here's Why We Think Aurisco PharmaceuticalLtd (SHSE:605116) Might Deserve Your Attention Today

Aurisco Pharmaceutical Co.,Ltd. to Report Q1, 2024 Results on Apr 29, 2024

Investor sentiment deteriorates as stock falls 17%

Aurisco Pharmaceutical Co.,Ltd. to Report Fiscal Year 2023 Results on Apr 30, 2024

Third quarter 2023 earnings released: EPS: CN¥0.32 (vs CN¥0.17 in 3Q 2022)

Investor sentiment improves as stock rises 20%

New minor risk - Share price stability

Second quarter 2023 earnings released: EPS: CN¥0.13 (vs CN¥0.19 in 2Q 2022)

Aurisco Pharmaceutical Gets Auxiton(R) (Dydrogesterone) as First Generic Approval in China

Aurisco Pharmaceutical Co.,Ltd. to Report First Half, 2023 Results on Aug 30, 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

No independent directors

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: CN¥0.17 (vs CN¥0.12 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.19 (vs CN¥0.13 in 2Q 2021)

First quarter 2022 earnings: EPS and revenues miss analyst expectations

No independent directors

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.12 (vs CN¥0.10 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.13 (vs CN¥0.10 in 2Q 2020)

Full year 2020 earnings released: EPS CN¥0.42 (vs CN¥0.52 in FY 2019)

Investor sentiment improved over the past week

New 90-day low: CN¥13.10

Investor sentiment deteriorated over the past week

New 90-day low: CN¥15.71

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

New 90-day low: CN¥16.38

Third quarter earnings released

Market bids up stock over the past week

Aurisco Pharmaceutical Co.,Ltd. has completed an IPO in the amount of CNY 343.17 million.

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령